Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 9.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,448,040 shares of the company’s stock after buying an additional 126,306 shares during the quarter. Geode Capital Management LLC owned approximately 2.04% of Nurix Therapeutics worth $32,544,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in NRIX. Amalgamated Bank grew its holdings in Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after acquiring an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares in the last quarter. Quest Partners LLC increased its holdings in Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the last quarter. ClariVest Asset Management LLC raised its stake in Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock valued at $1,318,000 after buying an additional 1,766 shares in the last quarter. Finally, Quarry LP lifted its holdings in Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after buying an additional 2,435 shares during the last quarter.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,437 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the completion of the sale, the insider now owns 50,670 shares in the company, valued at $1,231,281. This represents a 6.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $546,680.16. The trade was a 18.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,401 shares of company stock valued at $437,453. 9.80% of the stock is owned by corporate insiders.

Nurix Therapeutics Stock Down 2.1 %

Shares of Nurix Therapeutics stock opened at $19.57 on Thursday. The business has a fifty day simple moving average of $23.13 and a 200-day simple moving average of $22.40. Nurix Therapeutics, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $29.56. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -6.73 and a beta of 2.12.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NRIX shares. HC Wainwright lifted their price objective on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Oppenheimer upped their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. BMO Capital Markets began coverage on Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 target price on the stock. BTIG Research initiated coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $41.00 price objective on the stock. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.35.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.